MedTrace Logo

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

NCT01222923 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-10-18

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.

Conditions

  • Healthy

Interventions

DRUG

Risperidone

1 mg orally disintegrating tablets

Sponsors & Collaborators

  • Ranbaxy Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Evin H Sides III,, MD · AAIPharma

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2004-10-31
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222923 on ClinicalTrials.gov